热门资讯> 正文
NeoGenomics在Natera专利纠纷中获胜后集会
2025-08-29 20:45
- NeoGenomics (NASDAQ:NEO) shares climbed ~20% in the premarket on Friday after the company announced a major victory in a legal battle over a patent dispute with its rival cancer test developer Natera (NASDAQ:NTRA).
- In a statement on Friday, the company stated that a federal judge in North Carolina granted its motion for summary judgment after determining that Natera’s (NASDAQ:NTRA) asserted patents were invalid due to claims of trivial subject matter.
- The District Court for the Middle District of North Carolina has stated it will dismiss the NTRA’s claims with prejudice, meaning that another case over the same claims cannot be brought back to the court.
- The judgment allows NeoGenomics (NASDAQ:NEO) to commercialize its cancer test RaDaR ST assay, formerly known as RaDaR 1.1, without any constraints in the U.S.
More on NeoGenomics, Natera
- Natera, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
- NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
- Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies
- Natera GAAP EPS of -$0.74 misses by $0.13, revenue of $546.6M beats by $69.76M
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
